Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADSVF for Inclusion Body Myositis
NCT05032131Phase 1Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous adipose-derived stromal vascular fraction in inclusion body myositis (IBM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Tolerance of escalating doses of ADSVF at 30 days. Status: unknown.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT05032131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032131.